News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
nSEPIA aims to bring structure to an area long dominated by subjectivity
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Subscribe To Our Newsletter & Stay Updated
